Medexus Pharmaceuticals is a leading specialty pharmaceutical company with a strong North American commercial platform. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics.
Employees: 51-200
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
Mentions in press and media 20
| Date | Title | Description |
| 28.01.2025 | Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares | The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO a... |
| 24.08.2024 | The Rise of RNA Medicines: Borealis Biosciences and the Future of Kidney Disease Treatment | In the world of biotechnology, innovation is the lifeblood. Borealis Biosciences has emerged as a beacon of hope in the treatment of kidney diseases. Recently, the company raised $150 million in Series A financing, marking a significant mil... |
| 22.08.2024 | Trinity Life Sciences Announces New Customer Engagement Solutions | Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces new Customer Engagement solutions leveraging both Trinity’s deep commercial insight and recognized technology platform. The new ... |
| 08.03.2023 | Medexus Announces US$58.5 million in New Credit Facilities | - |
| 08.02.2023 | Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022 | - |
| 08.08.2022 | Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022 | Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023 Management to host conference call at 8:00 AM Easter... |
| 25.07.2022 | Medexus resubmits NDA as it still looks to repurpose a decades-old drug | The German drugmaker medac’s US subsidiary is hoping the second time is the charm for the company, as it is officially asking the FDA once again to approve its cancer drug. Medexus Pharmaceuticals resubmitted its reque... |
| 10.02.2022 | Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021 | Achieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected in second calendar quarter 2022 with final FDA decision anticipated 2-6 months after resubmission Available liquidity of $10.1 million... |
| 31.01.2022 | Medexus Schedules Third Quarter Fiscal 2022 Conference Call | TORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, February... |
| 04.11.2021 | Medexus Schedules Second Quarter Fiscal 2022 Conference Call | TORONTO and CHICAGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, November... |
Show more